Search our Database of Scientific Publications and Authors

I’m looking for a

    6623 results match your criteria Temporal Giant Cell Arteritis

    1 OF 133

    [Headaches in autoimmune diseases].
    Wiad Lek 2016 ;69(6):773-777
    Uniwersytet Medyczny w Lublinie, Polska.
    Vasculitides in autoimmune diseases are an important cause of secondary headaches. The article discusses the incidence of headache in primary and secondary vasculitides of the central nervous system. The symptoms of primary CNS vasculitis are presented. Read More

    The Treatment of Giant Cell Arteritis.
    Curr Treat Options Neurol 2017 Jan;19(1)
    The Scheie Eye Institute, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
    Opinion Statement: Giant cell arteritis (GCA) is a systemic inflammatory vasculitis affecting medium and large vessels with potentially sight and life-threatening complications. Early diagnosis and prompt treatment are imperative in order to prevent vision loss and progression of the disease. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are inflammatory markers which are elevated in the majority of patients and support the diagnosis of GCA among patients who present with typical symptoms. Read More

    Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice.
    Clin Exp Rheumatol 2017 Jan 23. Epub 2017 Jan 23.
    Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IDISSC), Madrid, Spain.
    Objectives: To assess the long-term continuation of MTX in a cohort of patients with GCA in daily clinical practice. Factors associated with its discontinuation rate were also investigated.

    Methods: A longitudinal study from 1991-2014, was performed. Read More

    A randomized, double-blind trial of abatacept (CTLA4-IG) for the treatment of giant cell arteritis.
    Arthritis Rheumatol 2017 Jan 30. Epub 2017 Jan 30.
    University of Pennsylvania, Philadelphia, Pennsylvania.
    Objective: To compare the efficacy of abatacept to placebo for giant cell arteritis (GCA).

    Methods: In this multicenter trial, patients with newly-diagnosed or relapsing GCA were treated with abatacept 10 mg/kg IV on days 1, 15, 29, week 8, together with prednisone. At week 12, patients in remission underwent a double-blinded randomization to continue monthly abatacept or switch to placebo. Read More

    A Unique Case of Systemic Lupus Erythematosus Pelvic Vasculitis.
    Case Rep Rheumatol 2016 29;2016:6347901. Epub 2016 Dec 29.
    Division of Rheumatology, Cooper University Hospital, Camden, NJ, USA.
    The clinical presentation of Systemic Lupus Erythematosus (SLE) is diverse and vasculitis can be a potential manifestation. Cutaneous lesions involving small vessels are the most frequent presentation. However, medium and large vessel vasculitis may present with life-threatening visceral manifestations. Read More

    Giant Cell Arteritis Incidentally Detected by Positron Emission Tomography-Computed Tomography in a Patient With Atypical Symptoms.
    J Clin Rheumatol 2017 Jan 24. Epub 2017 Jan 24.
    From the *Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin; Departments of †Nuclear Medicine and ‡Infectious Diseases, Tianjin First Central Hospital, Tianjin; and §Department of Radiology, The Sixth Affiliated People's Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.

    Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
    Expert Rev Clin Immunol 2017 Feb 6:1-16. Epub 2017 Feb 6.
    a Rheumatology Unit, Department of Internal Medicine , Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico , Reggio Emilia , Italy.
    Introduction: Giant cell arteritis and Takayasu arteritis are the two major forms of idiopathic large vessel vasculitis. High doses of glucocorticoids are effective in inducing remission in both conditions, but relapses and recurrences are common, requiring prolonged glucocorticoid treatment with the risk of the related adverse events. Areas covered: In this article, we will review the standard and biological treatment strategies in large vessel vasculitis, and we will focus on the current approaches to these diseases. Read More

    Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis.
    Proc Natl Acad Sci U S A 2017 Feb 23;114(6):E970-E979. Epub 2017 Jan 23.
    Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA 94305;
    Giant cell arteritis (GCA) causes autoimmune inflammation of the aorta and its large branches, resulting in aortic arch syndrome, blindness, and stroke. CD4(+) T cells and macrophages form organized granulomatous lesions in the walls of affected arteries, destroy the tunica media, and induce ischemic organ damage through rapid intimal hyperplasia and luminal occlusion. Pathogenic mechanisms remain insufficiently understood; specifically, it is unknown whether the unopposed activation of the immune system is because of deficiency of immunoinhibitory checkpoints. Read More

    Relative Frequencies of Arteritic and Nonarteritic Anterior Ischemic Optic Neuropathy in an Arab Population.
    J Neuroophthalmol 2017 Jan 17. Epub 2017 Jan 17.
    The Neuro-Ophthalmology Division (AMG, JRC, TMB, CK, TJM), Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, MD; and Neuro-Ophthalmology Division (TMB, ZMA-S, TJM), King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
    Background: To evaluate the relative frequencies of arteritic and nonarteritic anterior ischemic optic neuropathy (AION) in an Arab population and to compare and contrast these findings with known epidemiological data from Caucasian populations.

    Methods: A retrospective review of the medical records of all patients diagnosed with AION at the King Khaled Eye Specialist Hospital (KKESH) in Riyadh, Saudi Arabia, between 1997 and 2012.

    Results: Of 171 patients with AION, 4 had biopsy-proven giant-cell arteritis (GCA). Read More

    Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study.
    J Rheumatol 2017 Jan 15. Epub 2017 Jan 15.
    From the Department of Internal Medicine, and Biostatistics and Clinical Research Unit, and Department of Neurology, Caen University Hospital; University of Caen, Basse Normandie; University of Caen-Normandie, Inserm U919, Caen; Department of Internal Medicine, Limoges University Hospital, Limoges; Department of Internal Medicine, Bichat University Hospital, Paris; Department of Internal Medicine, Dijon University Hospital, Dijon, France. H. de Boysson, MD, MSc, Department of Internal Medicine, Caen University Hospital, and University of Caen, Basse Normandie; E. Liozon, MD, Department of Internal Medicine, Limoges University Hospital; D. Larivière, MD, Department of Internal Medicine, Bichat University Hospital; M. Samson, MD, PhD, Department of Internal Medicine, Dijon University Hospital; J.J. Parienti, MD, PhD, Biostatistics and Clinical Research Unit, Caen University Hospital; J. Boutemy, MD, Department of Internal Medicine, Caen University Hospital; G. Maigné, MD, Department of Internal Medicine, Caen University Hospital; N. Martin Silva, MD, Department of Internal Medicine, Caen University Hospital; K. Ly, MD, PhD, Department of Internal Medicine, Limoges University Hospital; E. Touzé, MD, PhD, Department of Neurology, Caen University Hospital, and University of Caen-Normandie, Inserm U919; B. Bonnotte, MD, PhD, Department of Internal Medicine, Dijon University Hospital; A. Aouba, MD, PhD, Department of Internal Medicine, Caen University Hospital, and University of Caen, Basse Normandie; K. Sacré, MD, PhD, Department of Internal Medicine, Bichat University Hospital; B. Bienvenu, MD, PhD, Department of Internal Medicine, Caen University Hospital, and University of Caen, Basse Normandie. Address correspondence to Dr. H. de Boysson, Department of Internal Medicine, Caen University Hospital, Avenue de la Côte de Nacre, 14000 Caen, France. E-mail: Accepted for publication November 9, 2016.
    Objective: Our aim was to describe patients with giant cell arteritis (GCA)-related stroke and to compare them with a control group of GCA patients without stroke.

    Methods: We created a retrospective multicenter cohort of patients with (1) GCA diagnosed according to the American College of Rheumatology criteria between 1995 and 2015, and (2) stroke occurring at the time of GCA diagnosis or occurring within 4 weeks of starting GCA therapy. The control group consisted of GCA patients without stroke. Read More

    Estimating the Cost of Illness of Giant Cell Arteritis in the United States.
    Rheumatol Ther 2017 Jan 13. Epub 2017 Jan 13.
    Global Medicines Program, Department of Global Health, University of Washington, Seattle, WA, USA.
    Introduction: Giant cell arteritis (GCA) is a chronic vasculitis affecting approximately 230,000 Americans. Limited data exist on the healthcare resource utilization and costs attributable to GCA. The objective of this study was to estimate the cost of illness in patients with GCA in the US. Read More

    Giant cell arteritis and vascular disease-risk factors and outcomes: a cohort study using UK Clinical Practice Research Datalink.
    Rheumatology (Oxford) 2017 Jan 11. Epub 2017 Jan 11.
    Boston Collaborative Drug Surveillance Program, Boston University School of Public Health, Lexington.
    Objective: To evaluate the associations between GCA and vascular diseases and other comorbidities in patients with GCA compared with non-vasculitis patients.

    Methods: Using the UK-based Clinical Practice Research Datalink we identified 9778 newly diagnosed GCA patients in 1990-2014, and up to 10 non-vasculitis patients randomly matched to each case on age, sex, practice and years of history before cohort entry. We compared the distributions of 9 different pre-existing vascular diseases and 11 other comorbidities, and risks of incident vascular diseases and other comorbidities after cohort entry between GCA and non-vasculitis patients. Read More

    Fever of unknown origin, giant cell arteritis, and aortic dissection.
    Z Rheumatol 2017 Feb;76(1):83-86
    Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
    Giant cell arteritis is one of the most frequent causes of pyrexia of unknown origin after infectious or malignant causes have been ruled out. In this case report we describe a 66-year old female patient, who after five weeks of remitting fever developed a life-threatening, painless severe aortic dissection. The timely use of modern imaging technologies such as magnetic resonance angiography or positron emission computed tomography could in the future be of help to recognize aortic involvement early and to avoid this devastating complication in patients with fever of unknown origin. Read More

    [Recent advances in the treatment of large vessel vasculitides].
    Orv Hetil 2017 Jan;158(1):5-12
    Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó u. 38-40., 1023.
    Giant cell arteritis and Takayasu arteritis classified to large vessel vasculitides have similar histopathology in the vascular wall proposing that these entities can be different phenotypes on a spectrum of a single disorder. Glucocorticoids are the mainstay of therapy combined with cyclophosphamide, azatioprine and mycofenolate mofetil, when it is required. However, a significant proportion of patients are glucocorticoid-dependent despite of the conventional disease-modifying antirheumatic drugs and suffer from serious side effects of the steroids, therefore alternate options for more effective disease management are needed. Read More

    Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis.
    Rheumatology (Oxford) 2017 Jan 7. Epub 2017 Jan 7.
    Translational Immunology, Department of Biomedicine
    Objectives: Autoantibodies are useful biomarkers for diagnosing and monitoring treatment in some autoimmune diseases. Antibodies against isoforms of 14-3-3 protein have been proposed as biomarkers for the presence of aortic aneurysm in large-vessel vasculitis (LVV). Here, we aimed to evaluate the diagnostic role and potential immunopathological involvement of anti-14-3-3 antibodies in newly diagnosed LVV patients. Read More

    A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.
    Am J Hum Genet 2017 Jan 29;100(1):64-74. Epub 2016 Dec 29.
    Instituto de Parasitología y Biomedicina "López-Neyra," CSIC, PTS Granada, Granada 18016, Spain.
    Giant cell arteritis (GCA) is the most common form of vasculitis in individuals older than 50 years in Western countries. To shed light onto the genetic background influencing susceptibility for GCA, we performed a genome-wide association screening in a well-powered study cohort. After imputation, 1,844,133 genetic variants were analyzed in 2,134 case subjects and 9,125 unaffected individuals from ten independent populations of European ancestry. Read More

    Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis.
    Semin Arthritis Rheum 2016 Aug 25. Epub 2016 Aug 25.
    Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia; Basil Hetzel Institute, The Queen Elizabeth Hospital, Woodville South, Australia.
    Background: Previous studies of mortality associated with GCA have shown conflicting results. We conducted a systematic review and meta-analysis to determine the mortality risk in GCA patients compared to the general population.

    Methods: We searched for published studies indexed in MEDLINE and EMBASE and the Cochrane database from inception to June 18, 2015 using the terms "giant cell arteritis" and "temporal arteritis" combined with the terms for death, mortality, and survival. Read More

    Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
    Semin Arthritis Rheum 2016 Nov 28. Epub 2016 Nov 28.
    Basel Pharmacoepidemiology Unit, Hospital Pharmacy, University of Basel, Basel, Switzerland; Boston Collaborative Drug Surveillance Program (BCDSP), Boston University School of Public Health, Lexington, MA; Hospital Pharmacy, University Hospital Basel, Basel, Switzerland. Electronic address:
    Objective: Giant cell arteritis (GCA) is an inflammatory vasculitis preferentially affecting large and medium-sized arteries. High-dose oral glucocorticoids (GCs) are the mainstay of GCA therapy. Using data from the UK Clinical Practice Research Datalink (CPRD), we examined the risk of oral GC-related serious adverse events (SAEs) in a UK population of patients with giant cell arteritis (GCA). Read More

    Pathology of Ischemic Optic Neuropathy.
    Arch Pathol Lab Med 2017 Jan;141(1):162-166
    From the Departments of Ophthalmology (Drs Patel and Margo), Pathology and Molecular Biology (Dr Margo), Morsani College of Medicine, University of South Florida, Tampa.
    Ischemic optic neuropathy (ION) describes a state of hypoxic injury of the optic nerve. Clinically, ION is divided into anterior and posterior forms defined by the presence or absence of optic disc swelling, respectively. It is further classified as arteritic when secondary to vasculitis, and nonarteritic when not. Read More

    Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis.
    Arthritis Rheumatol 2017 Jan;69(1):176-184
    Massachusetts General Hospital, Harvard Medical School, and Boston University School of Medicine, Boston.
    Objective: Giant cell arteritis (GCA) and the use of glucocorticoids have both been associated with increased risk of venous thromboembolism (VTE). However, the possibility of confounding by indication has not been investigated. We undertook this study to examine the temporal risk of VTE in GCA patients before and after GCA diagnosis, accounting for confounders including glucocorticoid treatment. Read More

    Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial.
    Semin Arthritis Rheum 2016 Nov 15. Epub 2016 Nov 15.
    Rheumatology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114. Electronic address:
    Objective: To report entry criteria and clinical features of patients with newly diagnosed and relapsing giant cell arteritis (GCA) enrolled in a randomized trial of tocilizumab, an interleukin-6 receptor-alpha inhibitor.

    Methods: Newly diagnosed GCA was defined as diagnosis ≤6 weeks before baseline. Relapsing GCA was defined as diagnosis >6 weeks before baseline with ≥2 consecutive weeks of prednisone ≥40mg/day. Read More

    Widespread headache as the first clinical manifestation of giant cell arteritis in patients affected by polymyalgia rheumatica.
    Reumatologia 2016 28;54(5):236-238. Epub 2016 Nov 28.
    Internal and Geriatric Department ASL NA 3 sud, Rheumatologic Outpatient Clinic hospital "Mariano Lauro", Sant'Agnello, Italy.
    Introduction: In giant cell arteritis (GCA) headache of new onset due to inflammatory involvement of the temporal artery (TA) represents a diagnostic criterion. A widespread headache (WH) with scalp tenderness due to cranial arteritis can represent another manifestation of GCA.

    Material And Methods: In 225 elderly patients with polymyalgia rheumatica (PMR) followed in our rheumatologic outpatient clinic from 2004 until June 2016, the frequency of WH as the first clinical manifestation of GCA was evaluated. Read More

    Anti-endothelial cell antibodies in vasculitis: A systematic review.
    Autoimmun Rev 2017 Feb 15;16(2):146-153. Epub 2016 Dec 15.
    INSERM U1016, Institut Cochin, Paris, France; CNRS UMR 8104, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; LABEX Inflamex, Université Sorbonne Paris Cité, 75013 Paris, France; Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares, Vascularites nécrosantes et sclérodermie systémique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address:
    Anti-endothelial cell antibodies (AECAs) are those that can bind to endothelial cells (ECs) via variable region-specific interactions. The identification and quantification of AECAs varies depending on the technique used. The best approach would be to combine at least two different methods. Read More

    A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis.
    Autoimmun Rev 2017 Feb 15;16(2):179-191. Epub 2016 Dec 15.
    Department of Clinical Immunology, SSB 4th floor, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Dhanwantari Nagar, Puducherry 605006, India. Electronic address:
    Takayasu's arteritis (TA) and Giant cell arteritis (GCA) comprise the large vessel vasculitides (LVV). Patients with LVV are treated with disease-modifying anti-rheumatic drugs (DMARDs), both conventional (cDMARDs) and biologic (bDMARDs). We undertook a scoping review to assess the effectiveness of cDMARDs in TA and GCA. Read More

    Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica.
    Clin Exp Rheumatol 2016 Dec 2. Epub 2016 Dec 2.
    Department of Rheumatology and Immunology, Klinikum Bad Bramstedt, Bad Bramstedt, Germany. Present address: Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Germany.
    Objectives: To date, no specific serum marker for giant cell arteritis and polymyalgia rheumatica has been established in routine practice. Therefore, the aim of this study was to examine whether immunoglobulin G4 serum concentrations could be a potential biomarker for the differentiation of both diseases.

    Methods: Serum immunoglobulin G4 (IgG4) concentrations were measured in patients with giant cell arteritis (n=41) and polymyalgia rheumatica (n=27) by an in-house enzyme-linked immunosorbent assay. Read More

    The association of vascular risk factors with visual loss in giant cell arteritis.
    Rheumatology (Oxford) 2016 Dec 10. Epub 2016 Dec 10.
    Norwich Medical School, University of East Anglia, Norwich.
    Objective: Blindness is a recognized complication of GCA; however, the frequency of and risk factors for this complication have not been firmly established. The aim of this study was to examine the incidence and determinants of blindness in patients with GCA, using a large international cohort.

    Methods: The analysis was conducted among subjects recruited into the Diagnosis and Classification Criteria in Vasculitis Study. Read More

    Clinical predictors of positive temporal artery biopsy.
    Can J Ophthalmol 2016 Dec 1;51(6):476-481. Epub 2016 Oct 1.
    Department of Ophthalmology, University of Ottawa Eye Institute, Ottawa, Ont. Electronic address:
    Objective: We investigated the ability of known clinical signs and symptoms, as well as common laboratory tests, to correctly predict a positive temporal artery biopsy.

    Design: A prospective cohort study.

    Participants: Consecutive patients in a tertiary referral centre undergoing temporal artery biopsy. Read More

    An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
    Ann Rheum Dis 2016 Dec 7. Epub 2016 Dec 7.
    Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
    Objectives: Randomised-controlled trials have recently proven the efficacy of the interleukin (IL)-6 receptor antagonist tocilizumab (TCZ) in giant cell arteritis (GCA). However, the mechanism of action of IL-6 blockade in this disease is unknown. Moreover, the role of regulatory T (Treg) cells in the pathogenesis of GCA remains underexplored. Read More

    The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.
    Health Technol Assess 2016 Nov;20(90):1-238
    Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK.
    Background: Giant cell arteritis (GCA) is a relatively common form of primary systemic vasculitis, which, if left untreated, can lead to permanent sight loss. We compared ultrasound as an alternative diagnostic test with temporal artery biopsy, which may be negative in 9-61% of true cases.

    Objective: To compare the clinical effectiveness and cost-effectiveness of ultrasound with biopsy in diagnosing patients with suspected GCA. Read More

    Treatment of giant-cell arteritis, a literature review.
    Mod Rheumatol 2017 Jan 13:1-8. Epub 2017 Jan 13.
    c Department of Internal Medicine , Centre Hospitalier Universitaire de Caen , Caen , Basse Normandie , France.
    Giant-cell arteritis (GCA) is the most common vasculitis in people aged more than 50 years. Despite the frequency of this disease, there is currently no international consensus on its therapeutic modalities. The aim of this study was to conduct a review on an international literature about the treatment of GCA, whatever the clinical pattern might be. Read More

    Perioperative Retinal Artery Occlusion: Risk Factors in Cardiac Surgery from the United States National Inpatient Sample 1998-2013.
    Ophthalmology 2017 Feb 30;124(2):189-196. Epub 2016 Nov 30.
    Department of Anesthesiology and Department of Ophthalmology and Visual Sciences, College of Medicine, University of Illinois at Chicago, Chicago, Illinois. Electronic address:
    Purpose: To study the incidence and risk factors for retinal artery occlusion (RAO) in cardiac surgery.

    Design: Retrospective study using the National Inpatient Sample (NIS).

    Methods: The NIS was searched for cardiac surgery. Read More

    A rare case of extensive cranial Langerhans cell histiocytosis, synchronously presenting as otitis externa and giant cell arteritis.
    J Surg Case Rep 2016 Dec 1;2016(11). Epub 2016 Dec 1.
    Department of Otolaryngology, Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom.
    Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder of unpredictable clinical course and varied modes of presentation. The spectrum of presentation is wide, ranging from isolated eosinophilic granulomas to multiple lesions and diffuse systemic involvement. We present the case of a 52-year-old man, who presented with an 8-week history of worsening otalgia and superficial temporal tenderness attributed to otitis externa within the community and subsequently giant cell arteritis. Read More

    Vascular endothelial growth factor levels and rheumatic diseases of the elderly.
    Arthritis Res Ther 2016 Dec 1;18(1):283. Epub 2016 Dec 1.
    Département de rhumatologie, Centre Hospitalier Universitaire Gabriel Montpied, 58, rue Montalembert, 63000, Clermont-Ferrand, France.
    Background: Increasing vascular endothelial growth factor (VEGF) has been reported in remitting symmetrical seronegative synovitis with pitting edema (RS3PE) syndrome, rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The aim of this study was to compare VEGF levels in patients over 60 years of age who have RS3PE, RA, PMR or GCA so as to determine whether elevated VEGF is specific for a rheumatic disease, the inflammation or edema that occurs with these pathological conditions.

    Methods: In this retrospective, multicentric study we assessed serum and plasma levels of VEGF in patients over 60 years of age with rheumatic diseases that were either de novo or of recent onset according to the initial clinical presentation, and we compared these patients with a control group. Read More

    Infections and the risk of incident giant cell arteritis: a population-based, case-control study.
    Ann Rheum Dis 2016 Nov 28. Epub 2016 Nov 28.
    Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland.
    Objectives: Alterations in the immune system and infections are suspected to increase susceptibility to giant cell arteritis (GCA). Recently herpes zoster has been directly implicated in the pathogenesis of GCA. We examined the association between prior infections, in particular herpes zoster, and incident GCA in a population-based cohort. Read More

    Intercellular adhesion molecule-1 polymorphisms, K469E and G261R and susceptibility to vasculitis and rheumatoid arthritis: a meta-analysis.
    Cell Mol Biol (Noisy-le-grand) 2016 Oct 31;62(12):84-90. Epub 2016 Oct 31.
    Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
    The aim of this study was to determine whether intercellular adhesion molecule-1 (ICAM-1) polymorphisms are associated with susceptibility to vasculitis or rheumatoid arthritis (RA). Meta-analyses were performed to assess the associations between K469E and G241R polymorphisms of ICAM-1 and vasculitis or RA. A total of 12 studies on 1,368 patients and 1,922 controls, which comprised 8 vasculitis studies and 4 RA studies, were included in the meta-analysis. Read More

    Diplopia: What to Double Check in Radiographic Imaging of Double Vision.
    Radiol Clin North Am 2017 Jan;55(1):69-81
    Department of Radiology, North Shore University Hospital, Northwell Health, 300 Community Drive, Manhasset, NY 11030, USA.
    When patients see double with both eyes open, known as "binocular diplopia," this may be a harbinger of underlying life-threatening causes. This article presents pertinent anatomy, critical abnormality, and radiographic features that should be double checked for in diplopia. Key areas requiring a double check using the acronym VISION include Vascular, Infectious and Inflammatory, the Scalp for giant cell arteritis, Sphenoid and Skull base in trauma, Increased intracranial pressure (pseudotumor cerebri), Onset of new headaches or psychosis, and Neoplasm. Read More

    Giant Cell Arteritis With Arteritic Anterior Ischemic Optic Neuropathy Is Bilateral Until Proven Otherwise.
    J Neuroophthalmol 2016 Dec;36(4):479
    Royal North Shore Hospital, Sydney, AustraliaUniversity of New South Wales, Sydney, AustraliaUniversity of Sydney, Sydney, AustraliaSydney Institute of Vision Science, Sydney, AustraliaDepartment of Ophthalmology, Prince of Wales Hospital, Sydney, AustraliaUniversity of New South Wales, Sydney, Australia.

    Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set.
    Open Access Rheumatol 2016 17;8:93-95. Epub 2016 Oct 17.
    Geriatric Rheumatologic Outpatient Clinic, Hospital "Mariano Lauro," Sant'Agnello, Naples, Italy.
    In the last few years, the relationship between polymyalgia rheumatica (PMR) and cancer has been considered with very different conclusions. In particular, in 2010, Ji et al examined the overall and specific cancer risks among Swedish subjects following hospitalization for PMR and giant cell arteritis and noted that the risk of cancer was highest in the first year after hospitalization (of 3941 total cancer diagnoses, 783 [19.1%] were in the first year). Read More

    Polymyalgia rheumatica: observations of disease evolution without corticosteroid treatment.
    Open Access Rheumatol 2016 1;8:45-49. Epub 2016 Apr 1.
    Division of Rheumatology, Department of Medicine, Monmouth Medical Center, Long Branch, NJ, USA.
    Objectives: The diagnostic diversity of polymyalgia rheumatica (PMR) can easily be obscured by the widespread use of corticosteroids (CSs) early in the disease course. This study observed the course of PMR without CSs and determined whether alternative medication could be useful.

    Methods: Seventy patients with new-onset PMR comprised phase 1. Read More

    1 OF 133